{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:56:52Z","timestamp":1792198612862,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,2]]},"DOI":"10.7759\/cureus.106312","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:38:16Z","timestamp":1775119096000},"source":"Crossref","is-referenced-by-count":3,"title":["Immune Endotype-Guided Precision Immunotherapy in Sepsis: From Transcriptomics to Bedside Application"],"prefix":"10.7759","author":[{"given":"Olurotimi J","family":"Badero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olutomiwa","family":"Omokore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ojeyemi","family":"Oore-ofe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bamikole","family":"Osibowale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Quadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temiloluwa","family":"Olayinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Olabode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E","family":"Kalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeyemi","family":"Adetola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam O","family":"Buari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyiola O","family":"Solanke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-025-08047-0","article-title":"Identification of transcriptomic sepsis endotypes in sub-Saharan Africa: derivation, validation, and global alignment in two Ugandan cohorts","volume":"51","author":"Cummings MJ","year":"2025","unstructured":"Cummings MJ, Lutwama JJ, Tomoiaga AS, et al.. Identification of transcriptomic sepsis endotypes in sub-Saharan Africa: derivation, validation, and global alignment in two Ugandan cohorts. Intensive Care Med. 2025, 51:1573-86. 10.1007\/s00134-025-08047-0","journal-title":"Intensive Care Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07761-0","article-title":"Characterization of sepsis inflammatory endotypes using circulatory proteins in patients with severe infection: a prospective cohort study","volume":"22","author":"Rica\u00f1o-Ponce I","year":"2022","unstructured":"Rica\u00f1o-Ponce I, Riza AL, de Nooijer AH, et al.. Characterization of sepsis inflammatory endotypes using circulatory proteins in patients with severe infection: a prospective cohort study. BMC Infect Dis. 2022, 22:778. 10.1186\/s12879-022-07761-0","journal-title":"BMC Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-025-00802-1","article-title":"Molecular endotypes in sepsis: integration of multicohort transcriptomics based on RNA sequencing","volume":"30","author":"Mekata K","year":"2025","unstructured":"Mekata K, Kyo M, Tan M, Shime N, Hirohashi N. Molecular endotypes in sepsis: integration of multicohort transcriptomics based on RNA sequencing. J Intensive Care. 2025, 30:30. 10.1186\/s40560-025-00802-1","journal-title":"J Intensive Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000001178","article-title":"Sepsis phenotypes, subphenotypes, and endotypes: are they ready for bedside care?","volume":"30","author":"Scherger SJ","year":"2024","unstructured":"Scherger SJ, Kalil AC. Sepsis phenotypes, subphenotypes, and endotypes: are they ready for bedside care?. Curr Opin Crit Care. 2024, 30:406-13. 10.1097\/MCC.0000000000001178","journal-title":"Curr Opin Crit Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04255-y","article-title":"A plea for personalization of the hemodynamic management of septic shock","volume":"26","author":"De Backer D","year":"2022","unstructured":"De Backer D, Cecconi M, Chew MS, et al.. A plea for personalization of the hemodynamic management of septic shock. Crit Care. 2022, 26:372. 10.1186\/s13054-022-04255-y","journal-title":"Crit Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1287415","article-title":"The immune landscape of sepsis and using immune clusters for identifying sepsis endotypes","volume":"15","author":"Tang G","year":"2024","unstructured":"Tang G, Luo Y, Song H, et al.. The immune landscape of sepsis and using immune clusters for identifying sepsis endotypes. Front Immunol. 2024, 15:1287415. 10.3389\/fimmu.2024.1287415","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkaf001","article-title":"Recent advances of precision immunotherapy in sepsis","volume":"13","author":"Arapis A","year":"2025","unstructured":"Arapis A, Panagiotopoulos D, Giamarellos-Bourboulis EJ. Recent advances of precision immunotherapy in sepsis. Burns Trauma. 2025, 13:tkaf001. 10.1093\/burnst\/tkaf001","journal-title":"Burns Trauma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13092139","article-title":"Immunodynamic disruption in sepsis: mechanisms and strategies for personalized immunomodulation","volume":"13","author":"Saavedra-Torres JS","year":"2025","unstructured":"Saavedra-Torres JS, Pinz\u00f3n-Fern\u00e1ndez MV, Nati-Castillo HA, et al.. Immunodynamic disruption in sepsis: mechanisms and strategies for personalized immunomodulation. Biomedicines. 2025, 13:10.3390\/biomedicines13092139","journal-title":"Biomedicines"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss RS","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013, 13:862-74. 10.1038\/nri3552","journal-title":"Nat Rev Immunol"},{"key":"ref10","article-title":"Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis","volume":"8","author":"Gao DN","year":"2015","unstructured":"Gao DN, Yang ZX, Qi QH. Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis. Int J Clin Exp Med. 2015, 8:18998-9005.","journal-title":"Int J Clin Exp Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103044","article-title":"Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities","volume":"61","author":"van der Slikke EC","year":"2020","unstructured":"van der Slikke EC, An AY, Hancock RE, Bouma HR. Exploring the pathophysiology of post-sepsis syndrome to identify therapeutic opportunities. EBioMedicine. 2020, 61:103044. 10.1016\/j.ebiom.2020.103044","journal-title":"EBioMedicine"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5339\/qmj.2019.qccc.4","article-title":"Sepsis care pathway 2019","volume":"2019","author":"Labib A","year":"2019","unstructured":"Labib A. Sepsis care pathway 2019. Qatar Med J. 2019, 2019:4. 10.5339\/qmj.2019.qccc.4","journal-title":"Qatar Med J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701618","article-title":"Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity","volume":"200","author":"Jensen IJ","year":"2018","unstructured":"Jensen IJ, Sjaastad FV, Griffith TS, Badovinac VP. Sepsis-induced T cell immunoparalysis: the ins and outs of impaired T cell immunity. J Immunol. 2018, 200:1543-53. 10.4049\/jimmunol.1701618","journal-title":"J Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400734","article-title":"Differential susceptibility to CD95 (Apo-1\/Fas) and MHC class II-induced apoptosis during murine dendritic cell development","volume":"7","author":"McLellan AD","year":"2000","unstructured":"McLellan AD, Terbeck G, Mengling T, et al.. Differential susceptibility to CD95 (Apo-1\/Fas) and MHC class II-induced apoptosis during murine dendritic cell development. Cell Death Differ. 2000, 7:933-8. 10.1038\/sj.cdd.4400734","journal-title":"Cell Death Differ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114655","article-title":"Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II","volume":"24","author":"Wakamatsu E","year":"2024","unstructured":"Wakamatsu E, Machiyama H, Toyota H, et al.. Indirect suppression of CD4 T cell activation through LAG-3-mediated trans-endocytosis of MHC class II. Cell Rep. 2024, 24:114655. 10.1016\/j.celrep.2024.114655","journal-title":"Cell Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.4103\/0972-5229.117054","article-title":"Sepsis induced immunosuppression: implications for secondary infections and complications","volume":"17","author":"Sundar KM","year":"2013","unstructured":"Sundar KM, Sires M. Sepsis induced immunosuppression: implications for secondary infections and complications. Indian J Crit Care Med. 2013, 17:162-9. 10.4103\/0972-5229.117054","journal-title":"Indian J Crit Care Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2013-1","article-title":"Epidemiology of sepsis in intensive care units in Turkey: a multicenter, point-prevalence study","volume":"22","author":"Baykara N","year":"2018","unstructured":"Baykara N, Akal\u0131n H, Arslanta\u015f MK, et al.. Epidemiology of sepsis in intensive care units in Turkey: a multicenter, point-prevalence study. Crit Care. 2018, 22:93. 10.1186\/s13054-018-2013-1","journal-title":"Crit Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03351-1","article-title":"Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness","volume":"24","author":"Lundberg OH","year":"2020","unstructured":"Lundberg OH, Lengquist M, Sp\u00e5ngfors M, et al.. Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness. Crit Care. 2020, 24:636. 10.1186\/s13054-020-03351-1","journal-title":"Crit Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S402586","article-title":"Relationship between the expression of PD-1 and CTLA-4 on T lymphocytes and the severity and prognosis of sepsis","volume":"16","author":"Wang L","year":"2023","unstructured":"Wang L, Zhang Z, Chen X, et al.. Relationship between the expression of PD-1 and CTLA-4 on T lymphocytes and the severity and prognosis of sepsis. Int J Gen Med. 2023, 16:1513-25. 10.2147\/IJGM.S402586","journal-title":"Int J Gen Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116453","article-title":"Targeting novel regulated cell death: ferroptosis, pyroptosis, and autophagy in sepsis-associated encephalopathy","volume":"174","author":"Sun J","year":"2024","unstructured":"Sun J, Fleishman JS, Liu X, Wang H, Huo L. Targeting novel regulated cell death: ferroptosis, pyroptosis, and autophagy in sepsis-associated encephalopathy. Biomed Pharmacother. 2024, 174:116453. 10.1016\/j.biopha.2024.116453","journal-title":"Biomed Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00602-9","article-title":"Dysregulated dendritic cells in sepsis: functional impairment and regulated cell death","volume":"29","author":"Zheng LY","year":"2024","unstructured":"Zheng LY, Duan Y, He PY, et al.. Dysregulated dendritic cells in sepsis: functional impairment and regulated cell death. Cell Mol Biol Lett. 2024, 29:81. 10.1186\/s11658-024-00602-9","journal-title":"Cell Mol Biol Lett"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.732612","article-title":"Sepsis inflammation impairs the generation of functional dendritic cells by targeting their progenitors","volume":"12","author":"Lu J","year":"2021","unstructured":"Lu J, Sun K, Yang H, et al.. Sepsis inflammation impairs the generation of functional dendritic cells by targeting their progenitors. Front Immunol. 2021, 12:732612. 10.3389\/fimmu.2021.732612","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour CW","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, et al.. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019, 321:2003-17. 10.1001\/jama.2019.5791","journal-title":"JAMA"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003084","article-title":"Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters","volume":"46","author":"Sweeney TE","year":"2018","unstructured":"Sweeney TE, Azad TD, Donato M, et al.. Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018, 46:915-25. 10.1097\/CCM.0000000000003084","journal-title":"Crit Care Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.10.012","article-title":"The immunology of sepsis","volume":"54","author":"van der Poll T","year":"2021","unstructured":"van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immunity. 2021, 54:2450-64. 10.1016\/j.immuni.2021.10.012","journal-title":"Immunity"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)00046-1","article-title":"Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study","volume":"4","author":"Davenport EE","year":"2016","unstructured":"Davenport EE, Burnham KL, Radhakrishnan J, et al.. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med. 2016, 4:259-71. 10.1016\/S2213-2600(16)00046-1","journal-title":"Lancet Respir Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-021-01620-5","article-title":"Pediatric sepsis biomarkers for prognostic and predictive enrichment","volume":"91","author":"Wong HR","year":"2022","unstructured":"Wong HR. Pediatric sepsis biomarkers for prognostic and predictive enrichment. Pediatr Res. 2022, 91:283-8. 10.1038\/s41390-021-01620-5","journal-title":"Pediatr Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkae073","article-title":"Aiming for precision: personalized medicine through sepsis subtyping","volume":"13","author":"Kolodyazhna A","year":"2025","unstructured":"Kolodyazhna A, Wiersinga WJ, van der Poll T. Aiming for precision: personalized medicine through sepsis subtyping. Burns Trauma. 2025, 13:tkae073. 10.1093\/burnst\/tkae073","journal-title":"Burns Trauma"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon DJ","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344:783-92. 10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok TS","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, et al.. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361:947-57. 10.1056\/NEJMoa0810699","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok JD","year":"2025","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, et al.. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2025, 392:11-22. 10.1056\/NEJMoa2407417","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"4","author":"Maini R","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, et al.. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999, 4:1932-9. 10.1016\/s0140-6736(99)05246-0","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega HG","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, et al.. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014, 371:1198-207. 10.1056\/NEJMoa1403290","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00542-7","article-title":"Sepsis endotypes identified by host gene expression across global cohorts","volume":"4","author":"Chenoweth JG","year":"2024","unstructured":"Chenoweth JG, Brandsma J, Striegel DA, et al.. Sepsis endotypes identified by host gene expression across global cohorts. Commun Med (Lond). 2024, 4:120. 10.1038\/s43856-024-00542-7","journal-title":"Commun Med (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/cc10112","article-title":"Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients","volume":"15","author":"Guignant C","year":"2011","unstructured":"Guignant C, Lepape A, Huang X, et al.. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care. 2011, 15:R99. 10.1186\/cc10112","journal-title":"Crit Care"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200903-0363OC","article-title":"Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial","volume":"180","author":"Meisel C","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, et al.. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009, 180:640-8. 10.1164\/rccm.200903-0363OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-678","article-title":"Monocyte deactivation in septic patients: restoration by IFN-gamma treatment","volume":"3","author":"D\u00f6cke WD","year":"1997","unstructured":"D\u00f6cke WD, Randow F, Syrbe U, et al.. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997, 3:678-81. 10.1038\/nm0697-678","journal-title":"Nat Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98960","article-title":"Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial","volume":"3","author":"Francois B","year":"2018","unstructured":"Francois B, Jeannet R, Daix T, et al.. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018, 3:10.1172\/jci.insight.98960","journal-title":"JCI Insight"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia F","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018, 19:108-19. 10.1038\/s41590-017-0022-x","journal-title":"Nat Immunol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24175","article-title":"Precision immunotherapy to improve sepsis outcomes: the immunosep randomized clinical trial","volume":"335","author":"Giamarellos-Bourboulis EJ","year":"2026","unstructured":"Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al.. Precision immunotherapy to improve sepsis outcomes: the immunosep randomized clinical trial. JAMA. 2026, 335:775-86. 10.1001\/jama.2025.24175","journal-title":"JAMA"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705835","article-title":"Adjunctive glucocorticoid therapy in patients with septic shock","volume":"378","author":"Venkatesh B","year":"20181","unstructured":"Venkatesh B, Finfer S, Cohen J, et al.. Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 20181, 378:797-808. 10.1056\/NEJMoa1705835","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705716","article-title":"Hydrocortisone plus fludrocortisone for adults with septic shock","volume":"378","author":"Annane D","year":"2018","unstructured":"Annane D, Renault A, Brun-Buisson C, et al.. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018, 378:809-18. 10.1056\/NEJMoa1705716","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior Phase III trial","volume":"44","author":"Shakoory B","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, et al.. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior Phase III trial. Crit Care Med. 2016, 44:275-81. 10.1097\/CCM.0000000000001402","journal-title":"Crit Care Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342603","article-title":"Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein","volume":"27","author":"Fisher CJ","year":"1996","unstructured":"Fisher CJ, Agosti JM, Opal SM, et al.. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996, 27:1697-702. 10.1056\/NEJM199606273342603","journal-title":"N Engl J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187015","article-title":"The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial","volume":"12","author":"Sch\u00e4dler D","year":"2017","unstructured":"Sch\u00e4dler D, Pausch C, Heise D, et al.. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One. 2017, 12:e0187015. 10.1371\/journal.pone.0187015","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546474","article-title":"Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies","volume":"16","author":"Zhang X","year":"2025","unstructured":"Zhang X, Zhang W, Zhang H, Liao X. Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies. Front Immunol. 2025, 16:1546474. 10.3389\/fimmu.2025.1546474","journal-title":"Front Immunol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd KE","year":"2020","unstructured":"Rudd KE, Johnson SC, Agesa KM, et al.. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020, 395:200-11. 10.1016\/S0140-6736(19)32989-7","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473093-immune-endotype-guided-precision-immunotherapy-in-sepsis-from-transcriptomics-to-bedside-application","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:38:17Z","timestamp":1775119097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473093-immune-endotype-guided-precision-immunotherapy-in-sepsis-from-transcriptomics-to-bedside-application"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":47,"URL":"https:\/\/doi.org\/10.7759\/cureus.106312","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,2]]}}}